GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Renovacor Inc (AMEX:RCOR) » Definitions » Shares Outstanding (EOP)

Renovacor (Renovacor) Shares Outstanding (EOP) : 16.77 Mil (As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Renovacor Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Renovacor's shares outstanding for the quarter that ended in Sep. 2022 was 16.77 Mil.

Renovacor's quarterly shares outstanding increased from Jun. 2022 (16.77 Mil) to Sep. 2022 (16.77 Mil). It means Renovacor issued new shares from Jun. 2022 to Sep. 2022 .

Renovacor's annual shares outstanding stayed the same from Dec. 2020 (16.76 Mil) to Dec. 2021 (16.76 Mil).


Renovacor Shares Outstanding (EOP) Historical Data

The historical data trend for Renovacor's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renovacor Shares Outstanding (EOP) Chart

Renovacor Annual Data
Trend Dec20 Dec21
Shares Outstanding (EOP)
16.76 16.76

Renovacor Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only 17.26 16.76 16.76 16.77 16.77

Competitive Comparison of Renovacor's Shares Outstanding (EOP)

For the Biotechnology subindustry, Renovacor's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Renovacor's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Renovacor's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Renovacor's Shares Outstanding (EOP) falls into.



Renovacor Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Renovacor  (AMEX:RCOR) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Renovacor Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Renovacor's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Renovacor (Renovacor) Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 8142, Greenwich, CT, USA, 06836
Renovacor Inc is a preclinical stage gene therapy company developing a pipeline of innovative and proprietary AAV-based gene therapies for BAG3 gene mutation-associated diseases in areas of high unmet medical need. Its therapeutic focus is on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy.
Executives
Joseph S Carroll officer: Chief Accounting Officer C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Gregory F Covino director C/O RICHARD W DAVIES HUBBELL INC, 684 DERBY MILFORD RD, ORANGE CT 06477
Joan Lau director C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Benz Edward J. Jr director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Needham Thomas E. Jr. director MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Frederick W Driscoll officer: Chief Financial Officer
Jonas Grossman director 17 STREET, SUITE 1600, NEW YORK NY 10004
Gbolahan Amusa director 17 STATE STREET 21 FLOOR, NEW YORK NY 10004
Magdalene Cook director, officer: Chief Executive Officer C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Matthew Killeen officer: Chief Scientific Officer C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Rtw Master Fund, Ltd. 10 percent owner C/O WALKERS CORPORATE LIMITED, 190 ELGIN AVENUE, GEORGE TOWN, GRAND CAYMAN E9 KY1-9008
Roderick Wong 10 percent owner C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Marc Semigran officer: Chief Medical Officer C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Wendy F Dicicco officer: Interim CFO

Renovacor (Renovacor) Headlines